Send to

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Collaborators (215)

Chia M, Peters M, Polasek J, Sajkov D, Seale P, Wheatley J, Bedert L, Decramer M, Driesen P, Fievez P, Flemale A, Martinot JB, Mentens Y, Ninane V, Péche R, Plas B, van Zandweghe L, Adalberto R, Carmo Moreira MA, Fritscher C, Gondim H, Jardim JR, Dancheva A, Kostov K, Lllieva-Fartunova V, Metev H, Osmanliev D, Rashkov Palaveev K, Taseva M, Troshanova E, Bai C, Baiqiang C, Li H, Lin Y, Tang Y, Wu Y, Xin J, Yao W, Backer V, Dahl R, Titlestad I, Arvin-Berod C, Boyer GR, Brouquieres D, Brousse C, Caillaud D, Castelnau O, Cavailles A, Chanez P, Claussner Paulignan M, Dupouy J, Gutgobert C, Jasnot JY, Le Merre C, Meziane L, Paganin F, Pegliasco H, Proust A, Raspaud C, Tarodo de la Fuente P, Verdier S, Andreas S, Bewig B, Büttner C, Eich A, Gebhardt R, Herth F, Kardos P, Keller C, Koch A, Korn S, Kronsbein J, Käßner F, Magnussen H, Mikloweit P, Pfeifer M, Schröder-Babo W, Schultebraucks R, Vogelmeier C, Knorr R, Neurohr C, Gaga M, Gourgoulianis K, Kakoura M, Kosmas E, Koulouris N, Papiris S, Siafakas N, Sichletides L, Tatsis G, Toubis M, Vassilakopoulos T, Panagiotis D, Balint B, Jedlinszki M, Meszaros I, Papp M, Radeczky E, Rajakay K, Schlezák J, Di Maria GU, Fabbri LM, Foresi A, Fracchia C, Paggiaro PL, Foschino MP, Potena A, Spanevello A, Papi A, de Munck DR, Pasma HR, Rudolphus A, van Noord JA, Brockway B, Epton M, Jones S, McWilliams T, Mills G, Quinn D, Walford E, Kelly E, Custodio V, Fernandez L, de Guia T, Jorge M, Mortera L, Roa C, Santiaguel J, Wang A, Asankowicz-Bargiel B, Batura-Gabryel H, Chwist-Nowak A, Mieszko Filipczyk G, Madra-Rogacka D, Pawlukiewicz M, Silber M, Wesolowski S, Astafyeva N, Ilkovich M, Ivleva A, Khokhlov A, Leshchenko I, Nikishenkova L, Shilkina N, Zhestkov A, Mishina I, Alekseeva E, Abdool-Gaffar M, Abdullah I, Bateman E, Irusen E, Jansen J, Joubert JR, Ras G, Alonso A, Arismendi E, Cejudo P, Echave Sustaeta JM, Farrero E, Ferrer A, Galdiz Iturri JB, Gutierrez Lara JA, Rodriguez-Roisin R, Roldan J, Perng WC, Hang LW, Huang MS, Kuo PH, Tsao CY, Wu RG, Abdelkader A, Benzarti M, Bouacha H, Chabbou A, Megdiche ML, Aktogu S, Altin S, Atis S, Caglayan B, Cetinkaya E, Cikrikcioglu S, Damar D, Ergun P, Erkan L, Evyapan F, Guclu SZ, Gulmez I, Ilgazli A, Karakurt S, Sayiner A, Uzaslan EK, Yildiz O, Dzyublyk O, Krasnokutskiy S, Mostoviy Y, Ostrovskiy M, Sevchuk S, Voeykova L, Iashyna L, Barnes NC, Calverley P, Chilvers ER, Elborn S, Hadfield JW, Langan J, Lawson R, Mahdi H, Mansur A, McKeith D, Morice A, Nordstrum M, Russell R, Sridharan K, Wilson AM, Winning A.

Author information

The authors' affiliations are listed in the Appendix.



Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored.


In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea were also monitored.


As compared with continued glucocorticoid use, glucocorticoid withdrawal met the prespecified noninferiority criterion of 1.20 for the upper limit of the 95% confidence interval (CI) with respect to the first moderate or severe COPD exacerbation (hazard ratio, 1.06; 95% CI, 0.94 to 1.19). At week 18, when glucocorticoid withdrawal was complete, the adjusted mean reduction from baseline in the trough forced expiratory volume in 1 second was 38 ml greater in the glucocorticoid-withdrawal group than in the glucocorticoid-continuation group (P<0.001); a similar between-group difference (43 ml) was seen at week 52 (P=0.001). No change in dyspnea and minor changes in health status occurred in the glucocorticoid-withdrawal group.


In patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocorticoid therapy. However, there was a greater decrease in lung function during the final step of glucocorticoid withdrawal. (Funded by Boehringer Ingelheim Pharma; WISDOM number, NCT00975195.).

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center